摘要
目的 评价磷酸西格列汀联合二甲双胍对新诊断II型糖尿病临床疗效及安全性。方法 86例初诊2型糖尿病随机分为对照组与试验组,各43例,2组均给予对症的常规治疗。对照组给予口服盐酸二甲双胍缓释片（500 mg）,每日3次;在对照组的基础上,试验组联合给予磷酸西格列汀片100 mg口服,每日1次。1个治疗周期为28 d,2组患者均给予3个周期治疗。比较2组临床疗效、治疗前后血清脂联素（ADP）、衔接蛋白酶活化因子1（APAF1）、25-羟维生素D3（D25-（OH）D3）以及胱抑素C（Cys C）水平以及不良反应发生情况。结果 治疗后,对照组临床总有效率为76.74%,显著低于试验组的93.02%（P〈0.05）。2组治疗后血清ADP、APAF1、Cys C水平均显著降低,且试验组显著小于对照组（P〈0.05）;血清D25-（OH）D3水平显著升高,且试验组显著大于对照组（P〈0.05）。对照组不良反应发生率为16.28%,试验组为6.98%,差异无统计学意义。结论 磷酸西格列汀联合二甲双胍对新诊断II型糖尿病的临床疗效显著,安全性高。
Objective To evaluate the efficacy and safety of phosphoric acid phosphate combined metformin in the treatment of diagnosis of type 2 iabetes mellitus . Methods A total of 86 cases with diagnosis of type 2 diabetes mellitus included in this study were dividing into control group and xperiment group with each 43 cases. The patients in the both groups were give regular treatment. Patients in the control group were given metformin ydrochloride sustained release tablets 500mg by oral administration with 3 times a day and patients in the experiment group revieved phosphoric acid hosphate by oral administration with once a day . A cycle of 2 groups of patients were 28 d, a total of 3 cycles of treatment. The ADP, APAF1 ,D25- （0H）D3） ,CysC and adverse drug reactions were compared between the two groups. Results T h e clinical efficacy in e x p e r i m e n t g r o u p w a s 93. 02% , hich significant higher than that in control group 76. 74% （ P 〈 0. 05 ） . The serum level of ADP, APAF1 and CysC decreased after treatment with xperiment group much lower than the control group （ P 〈 0. 05） . The serum D25-（OH）D31 elevated in the two groups with experiment group much igher than the control group （P 〈0. 05 ）. The adverse drug reactions was not statistically different between the two groups. Conclusion Phosphoricacid hosphate combined metformin in the treatment of diagnosis of type 2 diabetes mellitus was effective with high safety.
出处
《中国生化药物杂志》
CAS
2017年第4期198-200,共3页
Chinese Journal of Biochemical Pharmaceutics
关键词
磷酸西格列汀
二甲双胍
II型糖尿病
临床研究
安全性
phosphoric acid phosphate
metformin
t y p e 2 d i a b e t e s
clinical s t u d y
safety
